EAM
OCUL icon

Exome Asset Management’s Ocular Therapeutix OCUL Stock Holding History

Exome Asset Management’s Portfolio OCUL Stock Details OCUL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-193,600
Closed -$1.76M – 64
2024
Q1 		$1.76M Buy
+193,600
New +$1.37M 1.51% 28

Other funds holding OCUL

SR
Summer Road West Palm Beach, Florida $142M AUM 43.61% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2B AUM 444.09% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Exome Asset Management's OCUL Position: Q2 2024 in Review

Exome Asset Management sold out of Ocular Therapeutix (OCUL) in Q2 2024, closing a stake of 193,600 shares — an estimated $1.76M sold.

Exome Asset Management first reported a position in OCUL in Q1 2024 and held it in 1 quarter. The position peaked at $1.76M in Q1 2024. 150 funds tracked by Wall St. Rank hold OCUL as of Q2 2024.

  • Exome Asset Management reported no remaining Ocular Therapeutix position as of Q2 2024 after selling out during the quarter.
  • Exome Asset Management sold 193,600 Ocular Therapeutix shares in Q2 2024, an estimated $1.76M.
  • Exome Asset Management first reported a position in Ocular Therapeutix in Q1 2024 and held it in 1 quarter.
  • Exome Asset Management's Ocular Therapeutix position peaked at $1.76M in Q1 2024.
  • 150 funds tracked by Wall St. Rank held Ocular Therapeutix as of Q2 2024.

Based on Exome Asset Management's 13F filing for Q2 2024, filed 14 Aug 2024.